These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 7985153)

  • 1. [The relationship of the theophylline concentration in the saliva and the blood serum in patients with a broncho-obstructive syndrome].
    Tsoĭ AN; Gavrilenko LN; Kushkenbaeva BE; Kukes VG
    Ter Arkh; 1994; 66(8):42-4. PubMed ID: 7985153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A comparative study of the pharmacokinetics of oral preparations of theophylline].
    Tsoĭ AN; Gneushev ET; Maĭorova EM; Gavrilenko LN; Kunes VG
    Farmakol Toksikol; 1990; 53(5):39-42. PubMed ID: 2253747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic comparison of a once-daily and twice-daily theophylline delivery system.
    González MA; Kisicki J; Straughn AB
    Clin Ther; 1994; 16(4):686-92. PubMed ID: 7982257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical effectiveness of delayed-action theophylline preparations].
    Tsoĭ AN; Gavrilenko LN; Bogovskiĭ BP; Semenova LG; Iuldasheva LI
    Klin Med (Mosk); 1990 Sep; 68(9):72-5. PubMed ID: 2290338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring of theophylline treatment by saliva and plasma concentrations.
    Juntunen-Backman K; Backman A; Björkstén F; Finnilä MJ
    Allergol Immunopathol (Madr); 1988; 16(1):5-9. PubMed ID: 3381714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A dose-concentration relationship study in different dosage regimens for theophylline preparations: intravenous for euphylline and peroral for prolonged-action forms].
    Tsoĭ AN; Bogovskiĭ BP; Gavrilenko LN; Kushkenbaeva BE; Kukes VG
    Ter Arkh; 1990; 62(9):22-5. PubMed ID: 2281401
    [No Abstract]   [Full Text] [Related]  

  • 7. [Theopek absorption efficiency in chronic diseases of the large intestine].
    Kukes VG; Fazylov AV; Kirkin BV; Kurapov AP; Volchenok VI
    Eksp Klin Farmakol; 1993; 56(4):46-7. PubMed ID: 8220017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The design of oral sustained-release theophylline dosing after conversion from intravenous to oral therapy.
    Yamazaki M; Fukutomi O; Kondo N; Kato Z; Nakashima Y; Shinoda S; Agata H; Kondo T; Imaeda N; Orii T
    Int J Clin Pharmacol Ther; 1994 Nov; 32(11):625-31. PubMed ID: 7874380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion from intravenous aminophylline to sustained-release theophylline: computer simulation versus in vivo results.
    Hatton RC; Gotz VP; Robinson JD; Russell WL; Ryerson GG
    Clin Pharm; 1983; 2(4):347-52. PubMed ID: 6883961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The pharmacokinetic characteristics of theophylline in patients with chronic nonspecific intestinal diseases in relation to its routes of administration into the gastrointestinal tract].
    Kukes VG; Fazylov AV; Kirkin BV; Kurapov AP; Blinov IL
    Ter Arkh; 1993; 65(2):52-4. PubMed ID: 9133013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reliability and predictive value of salivary theophylline levels.
    Jaber M; Schneider AT; Goldstein S; Sergiou H; Bjornson L; Chiaramonte LT
    Ann Allergy; 1987 Feb; 58(2):105-8. PubMed ID: 3813126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The pharmacokinetics of theopek--a new Soviet prolonged-action drug form of theophylline--in patients with bronchial asthma].
    Belousov IuB; Abazova FI; Kholodov LE; Chervinskaia TA; Sokolov AV
    Farmakol Toksikol; 1989; 52(5):63-8. PubMed ID: 2599082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative steady-state bioavailability of Theo-24 and Theo-Dur in healthy men.
    Dockhorn RJ; Cefali EA; Straughn AB
    Ann Allergy; 1994 Mar; 72(3):218-22. PubMed ID: 8129214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Spirographic indicators and theophylline levels in the blood and saliva after oral administration of 2 euphylline preparations in patients with reversible bronchial obstruction].
    Biernacki W; Bestry-Fus I; Figielski G
    Pneumonol Pol; 1982 Dec; 50(12):647-52. PubMed ID: 7182819
    [No Abstract]   [Full Text] [Related]  

  • 15. [The monitoring of delayed-release theophylline therapy in bronchial asthma in children by determining the salivary concentration].
    Panta P; Nanulescu MV; Culea M; Palibroda N
    Pneumoftiziologia; 1998; 47(1):15-9. PubMed ID: 9932029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The pharmacodynamics of theophylline (euphylline)].
    Tsoĭ AN; Bogovskiĭ BP; Saprygina TV; Kniazev RM; Titova EV; Kukes VG
    Ter Arkh; 1993; 65(8):36-40. PubMed ID: 8211799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea.
    Ahn HW; Shin WG; Park KJ; Suh OK; Choi JH
    Res Commun Mol Pathol Pharmacol; 1999; 105(1-2):105-13. PubMed ID: 10850374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacokinetic research on theophylline].
    Tsoĭ AN; Gneushev ET; Bogovskiĭ BP; Kaz'mina EM; Abrosimov AG
    Farmakol Toksikol; 1987; 50(1):89-91. PubMed ID: 3556561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of two long-acting theophylline preparations in daily evening administration].
    Holzer R
    Wien Med Wochenschr; 1993; 143(2):37-42. PubMed ID: 8488685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The comparative efficacy of the prolonged-action theophylline preparations Theopek and Euphylong in elderly patients with chronic obstructive lung diseases].
    Salikova VV; Nonikov VE; Belousov IuB
    Ter Arkh; 1993; 65(8):41-4. PubMed ID: 8211801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.